Cochrane · systematic review · CD007834
Iron for the treatment of restless legs syndrome
Trotti, LM, Becker, LA · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Iron compared to placebo for the treatment of restless legs syndrome
Population: people with restless legs syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in IRLS severity scale score Iron vs placebo | no estimate extracted | 7 studies · 345 participants | Moderate Downgraded: imprecision, publication bias |
Change in any measure of restlessness Iron vs placebo | no estimate extracted | 8 studies · 370 participants | Moderate Downgraded: imprecision, publication bias |
Quality of life (dichotomous measure) Iron vs placebo | RR 2.01 [0.54, 7.45] | 2 studies · 39 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Change in quality of life (continuous measure) Iron vs placebo | no estimate extracted | 3 studies · 128 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Withdrew to use other RLS medication or because of inadequate RLS symptom control Iron vs placebo | RR 0.77 [0.41, 1.47] | 9 studies · 391 participants | Low Downgraded: imprecision, publication bias |
Adverse events Iron vs placebo | RR 1.48 [0.97, 2.25] | 6 studies · 298 participants | Moderate Downgraded: imprecision, publication bias |
Drop out due to adverse event Iron vs placebo | RR 1.91 [0.5, 7.26] | 9 studies · 398 participants | Low Downgraded: imprecision, publication bias |